BNP Paribas Asset Management
HRMY icon

BNP Paribas Asset Management’s Harmony Biosciences HRMY Stock Holding History

BNP Paribas Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Sell
9,812
-59,213
-86% -$1.87M ﹤0.01% 1335
2026
Q1 		$1.93M Sell
69,025
-455
-0.7% -$14.9K ﹤0.01% 1081
2025
Q4 		$2.6M Buy
69,480
+69,117
+19,040% +$2.27M ﹤0.01% 1011
2025
Q3 		$10K Hold
363
– – ﹤0.01% 1634
2025
Q2 		$11K Buy
+363
New +$11.7K ﹤0.01% 1734

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's HRMY Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Harmony Biosciences (HRMY) stake by 86% in Q2 2026, selling an estimated $1.87M and leaving 9,812 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #1335.

BNP Paribas Asset Management first reported a position in HRMY in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.6M in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • BNP Paribas Asset Management held 9,812 shares of Harmony Biosciences worth $357K as of Q2 2026.
  • BNP Paribas Asset Management sold 59,213 Harmony Biosciences shares in Q2 2026, an estimated $1.87M.
  • Harmony Biosciences made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1335 holding.
  • BNP Paribas Asset Management first reported a position in Harmony Biosciences in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Harmony Biosciences position peaked at $2.6M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.